ADAMTS13 testing: Why bother?

Academic Article

Abstract

  • In this issue of Blood, Kremer Hovinga and colleagues demonstrate that a lower level of initial plasmaADAMTS13activity (< 10%) is associated with higher risk of relapse in patients with TTP. Also, patients with a low plasma ADAMTS13 activity and high-titer inhibitor (≥ 2 BU) appear to have lower survival rate. These findings suggest a role for clinical testing of plasma ADAMTS13 activity and inhibitors in care of TTP patients.
  • Authors

    Published In

  • Blood  Journal
  • Digital Object Identifier (doi)

    Author List

  • Zheng XL
  • Start Page

  • 1475
  • End Page

  • 1476
  • Volume

  • 115
  • Issue

  • 8